secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001493152-24-018428
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma Q1 2024 net loss $5.8M; raises $10M in April, expects cash into Q2 2025
--------------------------------------------------------------------------------

- Q1 2024 revenue $0 vs $1.1M in Q1 2023; net loss $5.8M ($0.03 per share).
- Cash and equivalents $8.1M at March 31, 2024; subsequent $10M registered direct offering in April 2024.
- Active partnership discussions to advance MAT2203 into Phase 3 ORALTO trial in invasive aspergillosis.
- Compassionate use program has enrolled 22 patients with severe fungal infections; LNC platform abstracts at ASGCT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224018428/0001493152-24-018428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224018428/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer